RecruitingPhase 3NCT06779136
Phase III Clinical Study of MG-K10 Humanized Mab Injection in Subjects With Prurigo Nodularis
A Randomized, Double-blind, Placebo-controlled Phase III Study Evaluating the Efficacy and Safety of a Humanized MG-K10 Mab Injection in Subjects With Prurigo Nodularis.
Sponsor
Shanghai Mabgeek Biotech.Co.Ltd
Enrollment
160 participants
Start Date
Feb 26, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
A phase III clinical study to evaluate the efficacy and safety of a humanized MG-K10 mab injection in subjects with prurigo nodularis.administered every 4 weeks for 56 weeks.
Eligibility
Min Age: 18 YearsMax Age: 80 Years
Inclusion Criteria5
- eligibility criteria:
- voluntarily sign the ICF and comply with all the visits and research-related procedures required by the protocol;
- Both men and women were required to be ≥ 18 and ≤ 80 years old at the time of signing the informed consent;
- the duration of PN diagnosed by a dermatologist at the time of screening was ≥ 3 months;
- In the range of 1-10, WI-NRS≥7 in the past 24 h at screening; WI-NRS in the week before the baseline visit The average weekly score was ≥ 7 points.
Exclusion Criteria4
- There are skin diseases other than PN and mild atopic dermatitis (AD) that may interfere with the assessment of research outcomes.
- Patients who had a history of moderate to severe AD during the 6 months prior to the screening visit or screening visit.
- Receiving potent or super-potent TCS/TCI treatment within 2 weeks before or during screening.
- \) Evidence of active tuberculosis. 5) Participation in any other clinical study within 12 weeks or 5 half-lives prior to screening
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGPlacebo
Every four weeks, subcutaneous injection，Switch to MG-K10 treatment after 24 weeks of administration
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06779136
Related Trials
Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults
NCT0698861851 locations
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)
NCT06516952120 locations
Clinical Study of the Efficacy and Safety of SHR-1819 Injection in Adult Patients With Prurigo Nodularis
NCT065545091 location
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases
NCT0634271313 locations
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
NCT06516965119 locations